Drug Trial Radar · NCT04575311
A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: May 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Oct 20, 2020
Primary completion
Sep 22, 2021
Study completion Sep 22, 2021
Sponsor
- Lead sponsor
- Arcus Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers.
Conditions
- Healthy Volunteers
Interventions
AB680Drug
AB680 is a Cluster of Differentiation (CD)73 Inhibitor
PlaceboOther
Matching Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- AB680 Peak Plasma Concentration (Cmax)Time frame: Pre-dose; from First Dose Date to 15 Days After the Last Dose of AB680
- AB680 Time of Peak Concentration (Tmax)Time frame: Pre-dose; from First Dose Date to 15 Days After the Last Dose of AB680
- Area under the plasma concentration-time curve from time zero to t hours (AUC 0-t) of AB680Time frame: Pre-dose; from First Dose Date to 15 Days After the Last Dose of AB680
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.